SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study

Public health threat coming from a rapidly developing COVID-19 pandemic calls for developing safe and effective vaccines with innovative designs. This paper presents preclinical trial results of “Betuvax-CoV-2”, a vaccine developed as a subunit vaccine containing a recombinant RBD-Fc fusion protein...

Descripció completa

Dades bibliogràfiques

Autors principals:	Anna V. Vakhrusheva, Aleksandr V. Kudriavtsev, Nickolay A. Kryuchkov, Roman V. Deev, Maria E. Frolova, Konstantin A. Blagodatskikh, Milana Djonovic, Andrey A. Nedorubov, Elena Odintsova, Aleksandr V. Ivanov, Ekaterina A. Romanovskaya-Romanko, Marina A. Stukova, Artur A. Isaev, Igor V. Krasilnikov
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-08-01
Col·lecció:	Vaccines
Matèries:	SARS-CoV-2 RBD-based vaccine nanoparticle vaccine recombinant vaccine betulin COVID-19
Accés en línia:	https://www.mdpi.com/2076-393X/10/8/1290
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!